MTN-042 Clinical Flow Sheets

General Guidance

Guidelines for clinical management and temporary product hold/permanent discontinuation of study product are outlined in protocol section 9.

- In general, the IoR/designee has the discretion to hold study product temporarily at any time if s/he feels that continued product use would be harmful to the participant or interfere with treatment deemed clinically necessary.
- Unless otherwise specified in protocol section 9, the IoR/designee should immediately consult the PSRT for further guidance on resuming study product, continuing the hold temporarily, or progressing to permanent discontinuation of study product.
- The IoR/designee will document all temporary product holds and permanent discontinuations on applicable CRFs.
- Syndromic management of genital symptoms is acceptable while awaiting laboratory results if such practice is in line with the local standards of care.
- Observed single dose treatment should be provided whenever possible, per clinician discretion.
- When clinically appropriate, investigators should use oral or parenteral (in the case of syphilis, for example) medications when at all possible.

Conditions Requiring Hold/Discontinuation (1)

Condition	Temporary Hold	Permanent Discontinuation	
HIV Infection, PrEP or PEP Use			
Positive HIV Rapid Test Result	X		
Confirmed HIV infection		X	
Reported use of PrEP for HIV prevention prior to pregnancy			
outcome.		Х	
Reported use of PEP for potential HIV exposure	X		
Delivery/Pregnancy Outcome Related			
Report of admission to care for labor and delivery management, including induction of labor and cesarean delivery		Х	
Suspected onset of labor or rupture of membranes.	X		
Confirmed labor or rupture of membranes		Х	
Pregnancy Loss		Х	
Other Conditions/Events Requiring Hold or Discontinuation			
Non-therapeutic injection drug use		Х	
Unable or unwilling to comply with required study procedures, or otherwise might be put at undue risk to their/their infant's safety and well-being by continuing product use, according to the judgment of the IoR/designee.	x		
Coenrollment (consult PSRT regarding ongoing product use and other potential safety considerations)	x		
Holds/Discontinuations in Response to Adverse Events			
Allergic Reaction to the study product		X	
Grade 3 AE Related to Study Product Use not in Section 9.5	Х		
Grade 4 AE (regardless of relationship to study product)	Х		


Conditions Requiring Hold/Discontinuation (2)

Condition	Temporary Hold	Permanent Discontinuation
Conditions Requiring Hold/Discontinuation for oral Truvada Group	Only:	
Acquisition of hepatitis B infection		X
Initial result of ≥ Grade 2 creatinine clearance	X	
Confirmation of ≥ Grade 2 creatinine clearance after retesting within one week		X
Initial result of ≥ Grade 2 glycosuria or proteinuria	x	
Confirmation of ≥ Grade 2 glycosuria or proteinuria after retesting within one week		x
Conditions Requiring Hold/Discontinuation for Vaginal Ring Group	Only:	
Superficial epithelial disruption (abrasion/peeling) which has worsened after re-evaluation in 3-5 days	x	
Deep epithelial disruption (ulceration)	X	
Symptomatic, localized erythema or edema (area <50% of vulvar surface or combined vaginal and cervical surface) which has worsened after re-evaluation in 3-5 days	x	
Asymptomatic, localized erythema or edema (area <50% of vulvar surface or combined vaginal and cervical surface) which has worsened after re-evaluation at the next scheduled visit	x	
Generalized erythema or severe edema (area >50% of vulvar surface or combined vaginal and cervical surface)	x	
E Grade 2 genital bleeding (LoA#1)	X	
Unexpected Grade 1 genital bleeding due to deep epithelial disruption (LoA#1)	x	
Cervicitis (inflammation and/or friability)	X	
Erade 2 chorioamnionitis (leading to referral for delivery per SOC) (LoA#1)		x

Product Use by Grade

- Grade 1 or 2 (not specifically addressed in protocol section 9.5), regardless of relatedness to study product may continue product use
- Grade 3 (not specifically addressed in protocol section 9.5), judged to be **not related**, continue product use
- Grade 3 (not specifically addressed in protocol section 9.5) judged to be related
 - Temporarily hold product
 - Reassess weekly x 2 weeks
 - If \leq Grade 2 within 2 weeks, resume product
 - If not ≤ Grade 2 within 2 weeks, consult PSRT
- Grade 4, regardless of relationship, temporarily hold, consult PSRT

Product Use Management: HIV Infection



Product Use Management: Additional Conditions Requiring Product Hold


- Reported use of PEP for potential HIV exposure
- Suspected onset of labor or rupture of membranes.
- Unable or unwilling to comply with required study procedures, or otherwise might be put at undue risk to their/their infant's safety and well-being by continuing product use, according to the judgment of the IoR/designee (consult PSRT)
- Co-enrollment (consult PSRT)

HOLD product. Consult PSRT if required per protocol.

Product Use Management: Additional Conditions Requiring Permanent Discontinuation

- Acquisition of hepatitis B infection (for Truvada group only)
- ➤ Confirmation of ≥ Grade 2 creatinine clearance (for Truvada group only).
- ➤ Confirmation of ≥ Grade 2 glycosuria or proteinuria (for Truvada group only).
- Allergic Reaction to the Study Product
- Reported use of PrEP for HIV prevention prior to pregnancy outcome.
- Non-therapeutic injection drug use
- Confirmed labor or rupture of membranes
- Report of admission to care for labor and delivery management, including induction of labor and cesarean delivery
- Pregnancy Loss

→ PERMANENTLY DISCONTINUE product.




Protocol Reference: Section 9.5


Product Use Management: Sexually Transmitted Infections and Reproductive Tract Infections


CONTINUE product, unless permanent discontinuation guidelines apply.


Consult the PSRT if a permanent discontinuation is deemed necessary and instituted by the IoR/designee, Vaginally applied medications should not be used. Whenever possible, oral or parenteral medications should be used instead.

*Treat per local or current WHO guidelines, using observed single dose regimens whenever possible.











Product Use Management during VAGINAL RING use: Unexpected grade 1 genital bleeding



NOTE: recommended discretion be used to follow this management while approval is pending for LoA#1


Protocol Reference: Section 9.5, LoA#1

Product Use Management during VAGINAL RING use: Unexpected ≥ Grade 2 genital bleeding



NOTE: recommended discretion be used to follow this management while approval is pending for LoA#1

Product Use Management during VAGINAL RING use: Cervicitis (including inflammation and/or friability)



NOTE: recommended discretion be used to follow this management while approval is pending for LoA#1

Product Use Management during VAGINAL RING use : Genital petechia(e)/ genital ecchymosis

CONTINUE product and perform naked eye exam; further evaluation/treatment per clinician discretion

Product Use Management: ≥ Grade 2 chorioamnionitis



NOTE: recommended discretion be used to follow this management while approval is pending for LoA#1